메뉴 건너뛰기




Volumn 53, Issue DEC., 2005, Pages 1060-1064

Multiple myeloma: Treatment options for an incurable disease

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; HUMAN; MULTIPLE MYELOMA; PATHOLOGY; PROGNOSIS; SHORT SURVEY;

EID: 28644449685     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey
Times cited : (2)

References (37)
  • 1
    • 0026432631 scopus 로고
    • Nephrotoxic potential of Bence Jones proteins
    • Soloman A, Weiss DT, Kattine AA. Nephrotoxic potential of Bence Jones proteins [see comments]. N Eng J Med 1991;324:1845.
    • (1991) N Eng J Med , vol.324 , pp. 1845
    • Soloman, A.1    Weiss, D.T.2    Kattine, A.A.3
  • 2
    • 0028834450 scopus 로고
    • Role of light chain variable region in myeloma with light chain deposition disease: Evidence from an experimental model
    • Khamlichi AA, Rocca A, Touchard G, et al. Role of light chain variable region in myeloma with light chain deposition disease: evidence from an experimental model. Blood 1995;86:3655.
    • (1995) Blood , vol.86 , pp. 3655
    • Khamlichi, A.A.1    Rocca, A.2    Touchard, G.3
  • 3
    • 0029008826 scopus 로고
    • Renal disease and patient survival in light chain deposition disease
    • Pozzi C, Fogazzi GB, Banfi G, et al. Renal disease and patient survival in light chain deposition disease. Clin Nephrol 1995;43:281.
    • (1995) Clin Nephrol , vol.43 , pp. 281
    • Pozzi, C.1    Fogazzi, G.B.2    Banfi, G.3
  • 4
    • 0028276963 scopus 로고
    • Monoclonal proteins and renal disease
    • Kyle RA. Monoclonal proteins and renal disease. Annu Rev Med 1994;45:71.
    • (1994) Annu Rev Med , vol.45 , pp. 71
    • Kyle, R.A.1
  • 5
    • 0032992602 scopus 로고    scopus 로고
    • Renal failure and multiple myeloma: Pathogenesis and treatment of renal failure and management of underlying myeloma
    • Clark AD, Shetty A, Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Reviews 1999;13:79-90.
    • (1999) Blood Reviews , vol.13 , pp. 79-90
    • Clark, A.D.1    Shetty, A.2    Soutar, R.3
  • 6
    • 0033922451 scopus 로고    scopus 로고
    • Renal involvement in multiple myeloma: A 10-year study
    • Sakhuja V, Jha V, Varma S, et al. Renal involvement in multiple myeloma: a 10-year study. Renal Failure 2000;22:465-77.
    • (2000) Renal Failure , vol.22 , pp. 465-477
    • Sakhuja, V.1    Jha, V.2    Varma, S.3
  • 7
    • 6844252283 scopus 로고    scopus 로고
    • Long-term pamidronate treatment of advanced multiple myeloma reduces skeletal events
    • Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma reduces skeletal events. J Clin Oncol 1998;16:593-602.
    • (1998) J Clin Oncol , vol.16 , pp. 593-602
    • Berenson, J.R.1    Lichtenstein, A.2    Porter, L.3
  • 8
    • 0036729485 scopus 로고    scopus 로고
    • American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma
    • Berenson JR, Hillner BE, Kyle R, et al. American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719-36.
    • (2002) J Clin Oncol , vol.20 , pp. 3719-3736
    • Berenson, J.R.1    Hillner, B.E.2    Kyle, R.3
  • 10
    • 0028963248 scopus 로고
    • Peripheral blood stem cell transplant for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients
    • Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplant for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995;85:588.
    • (1995) Blood , vol.85 , pp. 588
    • Tricot, G.1    Jagannath, S.2    Vesole, D.3
  • 11
    • 0029804411 scopus 로고    scopus 로고
    • Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma
    • Govindarajan R, Jagannath S, Flick JT et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 1996;95:349-53.
    • (1996) Br J Haematol , vol.95 , pp. 349-353
    • Govindarajan, R.1    Jagannath, S.2    Flick, J.T.3
  • 12
    • 0028150642 scopus 로고
    • Multiple myeloma: Why does the disease escape from plateau phase?
    • Joshua DE, Brown RD, Gibson J. Multiple myeloma: why does the disease escape from plateau phase? Br J Haematol 1994;88:667-71.
    • (1994) Br J Haematol , vol.88 , pp. 667-671
    • Joshua, D.E.1    Brown, R.D.2    Gibson, J.3
  • 13
    • 0030005782 scopus 로고    scopus 로고
    • Plateau phase in multiple myeloma: An analysis of long-term follow-up of 432 patients
    • Divanen TM for the Finnish leukemia group. Plateau phase in multiple myeloma: an analysis of long-term follow-up of 432 patients. Br J Haematol 1996;92:834-9.
    • (1996) Br J Haematol , vol.92 , pp. 834-839
    • Divanen, T.M.1
  • 14
    • 0023870374 scopus 로고
    • A randomized trial of maintenance versus maintenance melphalan and prednisone in responding multiple myeloma patients
    • Belch A, Shelley W, Bergsagel D, et al. A randomized trial of maintenance versus maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 1988;57:94-9.
    • (1988) Br J Cancer , vol.57 , pp. 94-99
    • Belch, A.1    Shelley, W.2    Bergsagel, D.3
  • 15
    • 0028951419 scopus 로고
    • IFN alpha-2b versus no maintenance treatment during the plateau phase in multiple myeloma: A randomized study
    • Westin J, Rodjer S, Turesson I, et al. IFN alpha-2b versus no maintenance treatment during the plateau phase in multiple myeloma: a randomized study. Br J Haematol 1995;89:561-8.
    • (1995) Br J Haematol , vol.89 , pp. 561-568
    • Westin, J.1    Rodjer, S.2    Turesson, I.3
  • 16
    • 0029099343 scopus 로고
    • Randomized trial of IFN maintenance in multiple myeloma: A study of the Canada Clinical Trials group
    • Browman GP, Bergsagel DE, et al. Randomized trial of IFN maintenance in multiple myeloma: a study of the Canada Clinical Trials group. J Clin Oncol 1995;13:2354-60.
    • (1995) J Clin Oncol , vol.13 , pp. 2354-2360
    • Browman, G.P.1    Bergsagel, D.E.2
  • 17
    • 8944220233 scopus 로고    scopus 로고
    • A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
    • Intergroupe Francais du Myelome
    • Attal M, Harousseau JL, Stoppa AM, et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Eng J Med 1996;335:91-7.
    • (1996) N Eng J Med , vol.335 , pp. 91-97
    • Attal, M.1    Harousseau, J.L.2    Stoppa, A.M.3
  • 18
    • 0038147912 scopus 로고    scopus 로고
    • Double autologous transplantation improves survival of multiple myeloma patients: Final analysis of a prospective randomized study of the "Intergroupe Francophone du Myelome" (IFM 94)
    • abstract 7
    • Attal M, Harousseau JL, Facon T, et al. Double autologous transplantation improves survival of multiple myeloma patients: Final analysis of a prospective randomized study of the "Intergroupe Francophone du Myelome" (IFM 94). Blood 2002;100:abstract 7.
    • (2002) Blood , vol.100
    • Attal, M.1    Harousseau, J.L.2    Facon, T.3
  • 19
    • 0030043438 scopus 로고    scopus 로고
    • Graft-versus-myeloma effect: Proof of principle
    • Tricot G, Vesole DH, Jagannath S et al. Graft-versus-myeloma effect: proof of principle. Blood 1996;87:1196-8.
    • (1996) Blood , vol.87 , pp. 1196-1198
    • Tricot, G.1    Vesole, D.H.2    Jagannath, S.3
  • 20
    • 0033844816 scopus 로고    scopus 로고
    • Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: Predictive factors for response and long-term outcome
    • Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000;18:3031-7.
    • (2000) J Clin Oncol , vol.18 , pp. 3031-3037
    • Lokhorst, H.M.1    Schattenberg, A.2    Cornelissen, J.J.3
  • 22
    • 0029822773 scopus 로고    scopus 로고
    • Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome
    • Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996;88:2787-93.
    • (1996) Blood , vol.88 , pp. 2787-2793
    • Bensinger, W.I.1    Buckner, C.D.2    Anasetti, C.3
  • 23
    • 0000054477 scopus 로고    scopus 로고
    • Outcome of unrelated transplants in patients with multiple myeloma
    • abstract 1780
    • Ballen K, King R, Carston M, Reece D, Giralt S, Vesole D, et al. Outcome of unrelated transplants in patients with multiple myeloma. Blood 2000;96:abstract 1780, 414a.
    • (2000) Blood , vol.96
    • Ballen, K.1    King, R.2    Carston, M.3    Reece, D.4    Giralt, S.5    Vesole, D.6
  • 24
    • 0001190342 scopus 로고    scopus 로고
    • Allogeneic bone marrow transplantation in multiple myeloma: Single-center experience of 97 patients
    • abstract 993
    • Mehta J, Ayers D, Mattox S, et al. Allogeneic bone marrow transplantation in multiple myeloma: single-center experience of 97 patients. Blood 1997; 90: abstract 993, 225a.
    • (1997) Blood , vol.90
    • Mehta, J.1    Ayers, D.2    Mattox, S.3
  • 25
    • 85112358324 scopus 로고    scopus 로고
    • Allogeneic bone marrow transplantation: Role of T cell depletion and graft versus host disease
    • abstract 862
    • Huff CA, Noga SJ, Jones RJ et al. Allogeneic bone marrow transplantation: Role of T cell depletion and graft versus host disease. Blood 2000; 96: abstract 862,202a.
    • (2000) Blood , vol.96
    • Huff, C.A.1    Noga, S.J.2    Jones, R.J.3
  • 26
    • 85112398073 scopus 로고    scopus 로고
    • Allogeneic peripheral blood stem cell Transplantation for patients with multiple myeloma - Single centre experience
    • abstract 5276
    • Cheung B, Ackers C, Powles R, et al. Allogeneic peripheral blood stem cell Transplantation for patients with multiple myeloma - single centre experience. Blood 2000;96:abstract 5276,352b.
    • (2000) Blood , vol.96
    • Cheung, B.1    Ackers, C.2    Powles, R.3
  • 27
    • 4243330156 scopus 로고    scopus 로고
    • Graft versus myeloma. Clinical and basic aspects
    • May, Banff, CAN
    • Lokhorst H. Graft versus myeloma. Clinical and basic aspects. VIIIth International Myeloma Workshop, S20, May 2001, Banff, CAN.
    • (2001) VIIIth International Myeloma Workshop
    • Lokhorst, H.1
  • 28
    • 0033021543 scopus 로고    scopus 로고
    • Reinventing bone marrow transplantation: Nonmyeloablative preparative regimens and induction of graft-versus-malignancy effect
    • Champlin R, Khouri I, Kornblau S, et al. Reinventing bone marrow transplantation: nonmyeloablative preparative regimens and induction of graft-versus-malignancy effect. Oncology 1999;13:621-8.
    • (1999) Oncology , vol.13 , pp. 621-628
    • Champlin, R.1    Khouri, I.2    Kornblau, S.3
  • 29
    • 85112386084 scopus 로고    scopus 로고
    • Excellent outcome of non-myeloablative stem cell transplant (NMSCT) for good risk myeloma: The EBMT experience
    • abstract 872
    • Lalancette M, Rezvani K, Szydlo R et al. Excellent outcome of non-myeloablative stem cell transplant (NMSCT) for good risk myeloma: the EBMT experience. Blood 2000;96: abstract 872.
    • (2000) Blood , vol.96
    • Lalancette, M.1    Rezvani, K.2    Szydlo, R.3
  • 30
    • 0035353184 scopus 로고    scopus 로고
    • High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions
    • Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001;97:2574-9.
    • (2001) Blood , vol.97 , pp. 2574-2579
    • Badros, A.1    Barlogie, B.2    Morris, C.3
  • 31
    • 0003300168 scopus 로고    scopus 로고
    • Nonmyeloablative allogeneic transplantation with adjuvant dose escalated donor lymphocyte infusions for multiple myeloma
    • abstract 3379
    • Peggs KS, Williams CD, Chopra R, D'Sa S, et al. Nonmyeloablative allogeneic transplantation with adjuvant dose escalated donor lymphocyte infusions for multiple myeloma. Blood 2000;96:abstract 3379,781a.
    • (2000) Blood , vol.96
    • Peggs, K.S.1    Williams, C.D.2    Chopra, R.3    D'Sa, S.4
  • 32
    • 85112376366 scopus 로고    scopus 로고
    • Mini-allografts as salvage therapy in patients with heavily pretreated multiple myeloma
    • abstract 5066
    • Schaefer H, Bader P, Hebart H et al. Mini-allografts as salvage therapy in patients with heavily pretreated multiple myeloma. Blood 2000;96:abstract 5066, 306b.
    • (2000) Blood , vol.96
    • Schaefer, H.1    Bader, P.2    Hebart, H.3
  • 33
    • 0003274693 scopus 로고    scopus 로고
    • Non-myeloablative conditioning with fludarabine/melphalan for patients with multiple myeloma
    • abstract 1549
    • Giralt S, Weber D, Aleman A, et al. Non-myeloablative conditioning with fludarabine/melphalan for patients with multiple myeloma. Blood 1999;94:abstract 1549, 347a.
    • (1999) Blood , vol.94
    • Giralt, S.1    Weber, D.2    Aleman, A.3
  • 34
    • 0028362802 scopus 로고
    • Bone marrow angiogenesis and progression in multiple myeloma
    • Vacca A, Ribatti D, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87:503-8.
    • (1994) Br J Haematol , vol.87 , pp. 503-508
    • Vacca, A.1    Ribatti, D.2
  • 35
    • 0032748385 scopus 로고    scopus 로고
    • Anti-tumor activity of thalidomide in refractory multiple myeloma
    • Singhal S, Mehta J, Barlogie B, et al. Anti-tumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
    • (1999) N Engl J Med , vol.341 , pp. 1565-1571
    • Singhal, S.1    Mehta, J.2    Barlogie, B.3
  • 36
    • 0036843032 scopus 로고    scopus 로고
    • Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma
    • Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319-23.
    • (2002) J Clin Oncol , vol.20 , pp. 4319-4323
    • Rajkumar, S.V.1    Hayman, S.2    Gertz, M.A.3
  • 37
    • 0003251160 scopus 로고    scopus 로고
    • Biologic and clinical evaluation of Rituxan in the management of newly diagnosed multiple myeloma
    • abstract 1400
    • Hussein MA, Karam MA, McLain DA, et al. Biologic and clinical evaluation of Rituxan in the management of newly diagnosed multiple myeloma. Blood 1999;94:abstract 1400.
    • (1999) Blood , vol.94
    • Hussein, M.A.1    Karam, M.A.2    McLain, D.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.